Teva Pharmaceutical Industries Ltd (TEVA) Shares Sold by American Century Companies Inc.

American Century Companies Inc. trimmed its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 30.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,110,041 shares of the company’s stock after selling 495,886 shares during the quarter. American Century Companies Inc. owned approximately 0.11% of Teva Pharmaceutical Industries worth $21,035,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Schroder Investment Management Group raised its holdings in Teva Pharmaceutical Industries by 22.7% in the 3rd quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock valued at $106,290,000 after acquiring an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries by 4.5% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock valued at $106,271,000 after acquiring an additional 259,891 shares during the period. State Street Corp raised its holdings in Teva Pharmaceutical Industries by 5.1% in the 2nd quarter. State Street Corp now owns 4,763,692 shares of the company’s stock valued at $158,254,000 after acquiring an additional 232,924 shares during the period. Macquarie Group Ltd. raised its holdings in Teva Pharmaceutical Industries by 350.3% in the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after acquiring an additional 3,429,448 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 21.3% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,080,006 shares of the company’s stock valued at $45,924,000 after acquiring an additional 540,669 shares during the period. 51.93% of the stock is currently owned by institutional investors.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $19.33 on Thursday. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market cap of $19,890.00, a P/E ratio of -1.12, a P/E/G ratio of 1.43 and a beta of 0.59. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The firm’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter last year, the business posted $1.38 EPS. analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.69 earnings per share for the current fiscal year.

Several research firms have weighed in on TEVA. Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price target on the stock. in a report on Thursday, January 11th. ValuEngine raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Friday, January 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $24.00 target price on the stock. in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, Leerink Swann increased their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “underperform” rating in a research report on Friday, January 26th. Ten research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.26.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2018/02/15/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-american-century-companies-inc.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply